The impact of guidelines for the prevention of anemia on clinical outcome.
Guidelines for anemia management in renal disease are supported by substantial evidence demonstrating improvement in quality of life and objective markers of physical and cognitive performance. Randomized control studies demonstrating a survival benefit or improved cardiovascular outcomes are inconsistent. However, observational studies clearly demonstrate reduced mortality and hospitalization rate in patient cohorts on hemodiaLysis with hemoglobin measurements within the recommended target ranges. Data from patients in the predialysis phase of chronic kidney disease and those on peritoneal dialysis are limited and studies assessing the clinical impact of adherence to guidelines should be further explored in these populations. Available evidence suggests a proactive approach to anemia management should be practiced.
Pollock
Carol A
CA
Department of Medicine, University of Sydney, Renal Research Group, Kolling Institute, Royal North Shore Hospital, St. Leonards, New South Wales, Australia. carpol@med.usyd.edu.au
D000740:Anemia / Q000209:etiology / Q000517:prevention & control*; D004921:Erythropoietin / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D058085:Iron Compounds / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D006435:Renal Dialysis; D016896:Treatment Outcome
D006397:Hematinics; D058085:Iron Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin